<DOC>
	<DOCNO>NCT00542425</DOCNO>
	<brief_summary>The purpose study determine whether BA058 effective building bone postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>Phase 2 Dose-finding Study Evaluate Effects BA058 Treatment Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description>This randomize , parallel-group , multi-center , dose-finding study evaluate effect BA058 treatment otherwise healthy postmenopausal woman osteoporosis .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Primary The patient bone mineral density Tscore â‰¤ 2.5 lumbar spine hip ( femoral neck ) dual energy xray absorptiometry ( DXA ) . Women bone mineral density Tscore 2.0 low prior lowtrauma forearm , humerus , vertebral , sacral , pelvic , hip , femoral , tibial fracture within past 5 year , additional risk factor age 65 great strong maternal history osteoporosis define fracture relate osteoporosis osteoporosis determine BMD criterion , also study candidate . The patient good general health determine medical history physical examination without evidence clinically significant abnormality opinion Investigator . Primary History bone disorder ( e.g. , Paget 's disease ) postmenopausal osteoporosis . Prior treatment approve yet unapproved boneacting investigational agent . History carcinoma , nephrolithiasis urolithiasis within past five year osteosarcoma time . History radiotherapy ( radiation therapy ) .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>bone loss</keyword>
</DOC>